Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab
Donald M. McDonald, MD, PhD
Advertisement
Articles by Donald M. McDonald, MD, PhD
Dr. Donald McDonald from UCSF Comprehensive Cancer Center Explains Approved Angiogenesis Inhibitors
Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors
Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors
Advertisement
Latest Updated Articles
Dr. McDonald on Approved Angiogenesis InhibitorsPublished: September 22nd 2011 | Updated:
Dr. McDonald on the Continued Understanding of BevacizumabPublished: October 6th 2011 | Updated:
Dr. McDonald on Resistance to Angiogenesis InhibitorsPublished: September 8th 2011 | Updated:
Dr. McDonald on the Next Step for Angiogenesis InhibitorsPublished: September 13th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
5